Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.

14 May 2010

New research to improve treatment for oesophageal and upper stomach cancer

Poor diet, too much alcohol, smoking and increasing obesity could be leading to an epidemic of oesophageal and upper stomach cancer, according to a leading UK team of specialists at The University of Nottingham and Nottingham University Hospitals.

14 May 2010

Prometheus announces novel method for early detection of HACA during infliximab treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

14 May 2010

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

BioSphere Medical, Inc. - the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million.

14 May 2010

Increase in use of imaging scans underscores need for evidence-based protocols in cancer care

New research showing a more than 30 percent annual increase in the use of high-tech imaging scans in older cancer patients underscores the need for evidence-based protocols in cancer care, said MedSolutions, a leading provider of medical management services.

14 May 2010

DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary liver cancer

Celsion Corporation announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

14 May 2010

Merit Medical Systems to acquire BioSphere Medical

Merit Medical Systems, Inc. today announced that it has signed a definitive merger agreement to acquire BioSphere Medical, Inc. in an all cash transaction valued at approximately $96 million, inclusive of all common equity and Series A Preferred preferences.

14 May 2010

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2010.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

13 May 2010

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

In 1985 there was little hope for people with AIDS. Newspapers and television screens were filled with ghastly pictures of emaciated figures dying from a disease that had no cure.

13 May 2010

Robotic surgery keeps features intact in head, neck cancer removal procedures

Surgeons who perform procedures to remove head and neck cancers often work for six to eight hours on what is typically major, invasive surgery, which many times comes with facial disfigurement and debilitating side effects for the patient.

13 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

GTC Biotherapeutics, Inc. today reported its financial results for the first fiscal quarter ended April 4, 2010. The total net loss for the first quarter was $7.7 million, or $0.26 per share, compared to $10.4 million, or $0.99 per share, for the first quarter of 2009.

12 May 2010

CNA announces winners of 2010 CNA Employer Recognition Award

The Canadian Nurses Association announced today the winners of the 2010 CNA Employer Recognition Award. This prestigious prize honours employers who have shown an exceptional commitment to supporting registered nurses pursuing national certification in a range of nursing specialties.

12 May 2010

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer.

12 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

12 May 2010

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Critical Outcome Technologies Inc. announced today that it received a favourable Pre-Investigational New Drug (pre-IND) gap analysis report from an independent team that reviewed its novel oncology drug candidate COTI-2. This represents an important milestone as the Company draws closer to a Phase 1 clinical trial.

12 May 2010

Oncology News and Research

Further Reading

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

New research to improve treatment for oesophageal and upper stomach cancer

Prometheus announces novel method for early detection of HACA during infliximab treatment

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

Increase in use of imaging scans underscores need for evidence-based protocols in cancer care

DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary liver cancer

Merit Medical Systems to acquire BioSphere Medical

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

Robotic surgery keeps features intact in head, neck cancer removal procedures

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

CNA announces winners of 2010 CNA Employer Recognition Award

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Merck hosts R&D and Business Briefing

Evotec first-quarter operating loss decreases 93% to € 1.5 m

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

A best-practice guide for laboratory services in oncology trials eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News